Mineralys Therapeutics
MLYS
193 hedge funds and large institutions have $3.01B invested in Mineralys Therapeutics in 2025 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 68 increasing their positions, 63 reducing their positions, and 15 closing their positions.
238% more capital invested
Capital invested by funds: $889M → $3.01B (+$2.12B)
187% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 15
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
18.88% more ownership
Funds ownership: 100.79% → 119.67% (+19%)
17% more funds holding
Funds holding: 165 → 193 (+28)
8% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 63
87% less call options, than puts
Call options by funds: $2.54M | Put options by funds: $19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$44.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$36.2M |
| 5 |
Holocene Advisors
New York
|
+$26.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHAM
Integral Health Asset Management
New York
|
-$26M |
| 2 |
SOCM
SR One Capital Management
Wayne,
Pennsylvania
|
-$21.9M |
| 3 |
Jennison Associates
New York
|
-$18.6M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$10.9M |
| 5 |
SC
Stempoint Capital
New York
|
-$10.2M |
MLYS Hedge Fund Activity: Q3 2025 in Review
193 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q3 2025, worth a combined $3.01B — up 238% from $889M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new MLYS positions and 15 closed out — a net gain of 28 holders — while 68 added to existing stakes and 63 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $44.4M. The largest seller was Integral Health Asset Management, cutting an estimated $26M.
- 193 institutional investors held Mineralys Therapeutics (MLYS) as of Q3 2025, up from 165 in Q2 2025.
- Funds reported $3.01B of Mineralys Therapeutics stock for Q3 2025, up 238% quarter-over-quarter.
- 43 funds opened new Mineralys Therapeutics positions in Q3 2025 and 15 closed out, a net change of +28 holders.
- The largest Mineralys Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $44.4M added.
- The largest Mineralys Therapeutics seller in Q3 2025 was Integral Health Asset Management, an estimated $26M sold.
Based on aggregated 13F filings for Q3 2025.